Please login to the form below

Not currently logged in
Email:
Password:

JAK2 inhibitor

This page shows the latest JAK2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

Is acquisitive Celgene now eyeing CAR-T specialist Juno?

The rumours have started circulating just a few days after Celgene agreed a deal to acquire San Diego-based start-up Impact Bio, adding to its haematology business with a JAK2 ... inhibitor - fedratinib - in development for myelofibrosis and

Latest news

  • Celgene boosts haematology pipeline with $7bn Impact Bio deal Celgene boosts haematology pipeline with $7bn Impact Bio deal

    The US biotech is spending $1.1bn in upfront cash to buy Impact Bio and its late-stage drug candidate fedratinib, a JAK2 inhibitor in development for myelofibrosis and polycythaemia vera ... to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    The selective JAK1 and JAK2 inhibitor is being co-developed with Incyte and heads up "a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and ... Pfizer-partnered NGF inhibitor tanezumab for osteoarthritis

  • Incyte abandons solid tumour programme for Jakafi Incyte abandons solid tumour programme for Jakafi

    In the JANUS 1 trial, JAK1/JAK2 inhibitor Jakafi (ruxolitinib) failed to show a significant benefit when given alongside Roche's Xeloda (capecitabine) as a second-line treatment for patients with ... Incyte said that a phase II trial in pancreatic cancer

  • Eli Lilly files oral rheumatoid arthritis drug baricitinib in US Eli Lilly files oral rheumatoid arthritis drug baricitinib in US

    If approved, Incyte stands to receive another $100m milestone. Baricitinib is a selective JAK1 and JAK2 inhibitor and if approved will compete with Pfizer's Xeljanz (tofacitinib), currently the only JAK ... Analysts at Cowen &Co have previously suggested

  • Baxalta and CTI complete filing for Jakafi rival in US Baxalta and CTI complete filing for Jakafi rival in US

    Pacritinib is an oral kinase inhibitor - targeting JAK2, FLT3 RAK1 and CSF1R - and if approved would compete directly with Incyte and Novartis' fast-growing JAK2 inhibitor Jakafi (ruxolitinib) in the chronic ... With Jakafi and other JAK2 inhibitors,

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9,

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.

  • Pharma deals during November 2013 Pharma deals during November 2013

    While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise ... Cell Therapeutics

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics